4D pharma (DDDD) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Analysts’ Opinions Are Mixed on These Healthcare Stocks: Globus Medical (GMED) and 4D Molecular Therapeutics (FDMT)February 11, 2025 | markets.businessinsider.comChardan Capital Keeps Their Buy Rating on 4D Molecular Therapeutics (FDMT)February 10, 2025 | markets.businessinsider.comJefferies cuts 4D Molecular Therapeutics target to $40February 10, 2025 | msn.comPromising Interim Results Drive ‘Buy’ Rating for 4D Molecular TherapeuticsJanuary 13, 2025 | markets.businessinsider.comA Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 6 AnalystsJanuary 13, 2025 | benzinga.com4D Molecular price target lowered to $42 from $46 at BofAJanuary 12, 2025 | msn.com4D Molecular announces interim data on 4D-150 SPECTRA clincial trialJanuary 10, 2025 | markets.businessinsider.com4D Molecular focuses pipeline to prioritize 4D-150 in wet AMD, DMEJanuary 10, 2025 | markets.businessinsider.comWhat 5 Analyst Ratings Have To Say About 4D Molecular TherapeuticsDecember 18, 2024 | benzinga.com4D Molecular price target lowered to $46 from $79 at BofADecember 18, 2024 | markets.businessinsider.com4D Molecular announces publication of 4D-150 preclinical dataDecember 17, 2024 | markets.businessinsider.com4D Molecular Therapeutics’ Positive Q3 and Strategic AdvancesNovember 16, 2024 | markets.businessinsider.comBarclays Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)November 14, 2024 | markets.businessinsider.comPromising Clinical Data and Market Potential Justify Buy Rating for 4D Molecular TherapeuticsSeptember 20, 2024 | markets.businessinsider.comBarclays Sticks to Its Buy Rating for 4D Molecular Therapeutics (FDMT)September 19, 2024 | markets.businessinsider.com4D Molecular Therapeutics (FDMT) Receives a Buy from RBC CapitalSeptember 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for 4D Molecular Therapeutics Amidst Strong Financials and Promising PipelineAugust 13, 2024 | markets.businessinsider.comBuy Rating for 4D Molecular Therapeutics: Promising Future Based on Product Efficacy and Strategic Growth ProspectsJuly 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Applied Therapeutics (APLT) and Oric Pharmaceuticals (ORIC)July 19, 2024 | markets.businessinsider.comBuy Rating for 4D Molecular Therapeutics Based on Promising Phase II Trial Results for 4D-150 Gene TherapyJuly 19, 2024 | markets.businessinsider.com4D Molecular Therapeutics Goes Neck To Neck With Rival, Shares New Phase 2 Data For Its Wet AMD CandidateJuly 19, 2024 | msn.comPeeling Back The Layers: Exploring 4D Molecular Therapeutics Through Analyst InsightsJuly 19, 2024 | benzinga.com4D Molecular Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)March 1, 2024 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About 4D Molecular TherapeuticsFebruary 7, 2024 | markets.businessinsider.com4D Molecular Therapeutics up 3%, prices $300M equityFebruary 7, 2024 | msn.com4D Molecular Shares Hit 52-Week High After 4D-150 Eye Treatment TrialFebruary 5, 2024 | marketwatch.comHow to Trade a Surging 4D Molecular TherapeuticsFebruary 5, 2024 | realmoney.thestreet.comAnalysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Boston Scientific (BSX)February 5, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Valeo Pharma (OtherVPHIF) and AbbVie (ABBV)February 5, 2024 | markets.businessinsider.comIndian pharma firm Dr Reddy's beats Q3 profit view on strong US, European businessesJanuary 30, 2024 | news.yahoo.comAnalysts Offer Insights on Healthcare Companies: Merus (MRUS), 4D Molecular Therapeutics (FDMT) and Inari Medical (NARI)November 27, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Xenon (XENE), Adverum Biotechnologies (ADVM) and 4D Molecular Therapeutics (FDMT)November 11, 2023 | markets.businessinsider.comPositive Clinical Trial Results and Future Prospects Reinforce Buy Rating for 4D Molecular Therapeutics: An Analysis by Geulah LivshitsNovember 2, 2023 | markets.businessinsider.comBMO Capital Sticks to Their Buy Rating for 4D Molecular Therapeutics (FDMT)July 11, 2023 | markets.businessinsider.com4D Molecular Poised For Success: FDA Discussion And Solid Position In Competitive Genetic Medicine Space, Says AnalystJuly 5, 2023 | msn.com4D Molecular Down 25% After Wet AMD Drug UpdateApril 28, 2023 | marketwatch.comWhat's Going On With 4D Molecular Therapeutics Stock TodayApril 27, 2023 | markets.businessinsider.comMicrobiome Therapeutics Market Current Trends, Segmentation, Key Players and Analysis Till 2035March 24, 2023 | marketwatch.comPharmacy Management System Market Scenario 2023 to 2028: New Developments, Economic Situation and Growth ProjectionFebruary 14, 2023 | marketwatch.comHuman Microbiome Market Report (2022 to 2030) – Obiome, 4D Pharma, Vedanta Biosciences, Second Genome, Ferring PharmaceuticalsJanuary 20, 2023 | finance.yahoo.com4D Pharma rescue by Armistice to face voteDecember 30, 2022 | thetimes.co.uk4D pharma plc (DDDD.L)October 5, 2022 | finance.yahoo.comThe past year for 4D Molecular Therapeutics (NASDAQ:FDMT) investors has not been profitableSeptember 26, 2022 | nasdaq.com4D pharma plc (“4D pharma”) Receives Notice of Delisting From NasdaqJune 30, 2022 | apnews.comWoodford stock pick 4D Pharma collapsesJune 25, 2022 | thetimes.co.ukUpdate on Suspension of TradingJune 24, 2022 | finance.yahoo.com4D Pharma outlines phase II plans for promising cancer drug candidateMay 27, 2022 | proactiveinvestors.com.auHere’s why the 4D Pharma (LON:DDDD) share price is surging todayMay 17, 2022 | fool.co.uk4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International ConferenceMay 17, 2022 | finance.yahoo.com4D pharma conference poster underlines safety and potential efficacy of asthma drug candidateMay 17, 2022 | proactiveinvestors.com Get 4D pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for DDDD and its competitors with MarketBeat's FREE daily newsletter. Email Address DDDD Media Mentions By Week DDDD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DDDD News Sentiment▼0.000.61▲Average Medical News Sentiment DDDD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DDDD Articles This Week▼00▲DDDD Articles Average Week Get 4D pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for DDDD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Scancell News Ondine Biomedical News Redx Pharma News e-therapeutics News Futura Medical News Poolbeg Pharma News Sareum News ImmuPharma News Synairgen News Arecor Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:DDDD) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredCritical ‘Buy Now’ Alert on My Favorite Stock!My absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
